Galectin Inhibitor
- 1
- 2
-
GB1490
0 ImagesGB1490 is an orally active galectin inhibitor with Kd values of 0.4 μM and 2.7 μM for galectin-1 and galectin-3, respectively.
-
N-Acetyllactosamine (Standard)
0 ImagesCat. No.: HY-126854RCAS No.: 32181-59-2Synonyms: N-Acetyl-D-lactosamine (Standard)N-Acetyllactosamine (Standard) is the analytical standard of N-Acetyllactosamine. This product is intended for research and analytical applications. N-Acetyllactosamine (N-Acetyl-D-lactosamine), a nitrogen-containing disaccharide, is a galectin-3 inhibitor, which is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects[1][2][3][4].
-
Galectin-4-IN-3
0 ImagesCat. No.: HY-157821CAS No.: 1044566-26-8Galectin-4-IN-3 (Compound 11) is a Galectin 4C inhibitor, with a Kd of 160 μM.
-
Galectin-3/galectin-8-IN-2
0 ImagesCat. No.: HY-155192Galectin-3/galectin-8-IN-2 (Compound 57) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 12.8 μM and 2.06 μM respectively. Galectin-3/galectin-8-IN-2 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-2 can be used for research of cancer and tissue fibrosis.
-
Galectin-8-IN-2
0 ImagesCat. No.: HY-157822CAS No.: 1044566-24-6Galectin-8-IN-2 (Compound 10) is a galectin-8N inhibitor.
-
Dual Galectin-3/EGFR-IN-1
0 ImagesCat. No.: HY-170543Dual Galectin-3/EGFR-IN-1 (Compound 29) is the dual inhibitor for Galectin-3 and EGFR with the KD of 52.29 μM and 3.31 μM. Dual Galectin-3/EGFR-IN-1 inhibits TGF-β-induced hepatic stellate cell (HSCs) activation, induces apoptosis in LX-2 cell, and exhibits anti-liver fibrotic efficacy.
-
Galectin-3-IN-7
0 ImagesCat. No.: HY-179410Galectin-3-IN-7 is a selective Galectin-3 inhibitor with a Kd of 5.7 nM and shows 390-fold selectivity over Gal-1. Galectin-3-IN-7 can downregulate profibrotic signaling such as ACTA2, COL1A2, and FN1 in TGFβ-stimulated LX2 hepatic stellate cells. Galectin-3-IN-7 can be used for the research of fibrosis.
-
Gal-1-IN-1
0 ImagesCat. No.: HY-181648CAS No.: 3059548-99-8Gal-1-IN-1 is a potent and selective human galectin-1 (hGal-1) inhibitor with a Ki of 0.022 μM. Gal-1-IN-1 blocks hGal-1 binding to tumor cells and suppresses human galectin-1-induced pre-apoptosis state. Gal-1-IN-1 reduces hGal-1-expressing cancer cell viability. Gal-1-IN-1 can be used for the research of breast cancer.
-
Galectin-4-IN-2
0 ImagesCat. No.: HY-157820CAS No.: 1044566-28-0
-
Apoptosis inducer 8
0 ImagesCat. No.: HY-147865CAS No.: 2470024-51-0Apoptosis inducer 8 (Compound 7c) is a galectin-1 (gal-1) mediated apoptosis-inducing agent against global major leading lung cancer burden. Apoptosis inducer 8 significantly reduced the gal-1 protein level. Apoptosis inducer 8 is also a PET imaging agent.
-
Galectin-3-IN-4
0 ImagesCat. No.: HY-163407CAS No.: 2496515-38-7Galectin-3-IN-4 (compound 5) is a carboxamide analog. Galectin-3-IN-4 is a potent, selective, and orally bioavailable inhibitor of human and mouse galectin-3, with IC50 values of 21 and 167 nM for hGal-3 and mGal-3, respectively. Galectin-3-IN-4 has IC50 values of 1580 and 2750 nM for hGal-1 and hGal-9, respectively.
-
HFB200901
0 ImagesCat. No.: HY-P992366HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRASG12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8+ T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination.
-
Galectin-3-IN-2
0 ImagesCat. No.: HY-144313CAS No.: 2883648-71-1Galectin-3-IN-2 (Compound 9) is a potent multivalent inhibitor of galectin-3 (Gal-3; IC50=8.3 μM). Galectin-3 participates in many cancer-related metabolic processes.
-
Galectin-3-IN-6
0 ImagesCat. No.: HY-173235CAS No.: 2604662-64-6Galectin-3-IN-6 is a human and murine galectin-3 (Gal-3) inhibitor, with an IC50 of 12 nM against human galectin-3, an IC50 of 12.6 nM against mutant murine galectin-3 (V160A), and a Kd of 13 nM for human galectin-3, as well as oral bioavailability. Galectin-3-IN-6 reduces the levels of liver fibrosis markers type I collagen and α-smooth muscle actin in mouse models of acute liver injury and fibrosis. Galectin-3-IN-6 can be used for the research of acute liver injury and fibrosis.
-
Galectin-3-IN-3
0 ImagesCat. No.: HY-163405CAS No.: 2491661-50-6Galectin-3-IN-3 (Compound 4) is an orally active and selective inhibitor of Gal-3, with IC50 values of 11 nM and 84 nM against mGal-3 and hGal-3 respectively.
-
CHI3L1-IN-6
0 ImagesCat. No.: HY-180937CAS No.: 1914772-75-0CHI3L1-IN-6 (Compound 9e) is a CHI3L1 inhibitor with a Kd of 19.11 μM for hCHI3L1. CHI3L1-IN-6 blocks CHI3L1-Galectin-3 interaction. CHI3L1-IN-6 reduces STAT3 signaling. CHI3L1-IN-6 exhibits anti-cancer activity against glioblastoma.
-
Olitigaltin (Standard)
0 ImagesCat. No.: HY-19940RCAS No.: 1450824-22-2Synonyms: TD139 (Standard); GB0139 (Standard)Olitigaltin (Standard) is the analytical standard of Olitigaltin (HY-19940). This product is intended for research and analytical applications. TD139 is a synthetic galectin-3 inhibitor. TD139 has high affinity for galectin-3 with a Kd of 68 nM, a Kd of 0.22 μM for galectin-1, and a Kd of 38 μM for galectin-7.
-
Galectin-3-IN-5
0 ImagesCat. No.: HY-162789Galectin-3-IN-5 (Compound 20) is an orally active inhibitor of galectin-3 (Gal-3), with an IC50 value of 9.2 nM against hGal-3.
-
Galectin-8N-IN-2
0 ImagesCat. No.: HY-163900CAS No.: 3055149-84-0Galectin-8N-IN-2 (compound 2) is a potent and selective Galectin-8N inhibitor with a Ki value of 74 μM.
- 1
- 2
